

## HEAD CT FIRST HUMAN PILOT SITE ACTIVATION AT ROYAL MELBOURNE HOSPITAL

Installation underway at Royal Melbourne Hospital ahead of human imaging trial commencement

**Adelaide, Australia, 4 February 2026:** Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode X-ray technology for health and security markets globally, is pleased to provide a human imaging trial progress update for Micro-X's Head CT scanner for stroke.

### Key points:

- **Activation of first hospital trial site in progress at the Royal Melbourne Hospital, a world-leading Comprehensive Stroke Care Centre, enabling world first human imaging using Micro-X Head CT**
- **Human pilot study is designed to support future regulatory applications for Head CT scanner for stroke.**
- **Additional test benches are in advanced stages of construction to enable two further sites to participate in the human imaging trials.**

The installation and commissioning of the Head CT test bench at the Royal Melbourne Hospital (RMH) is in progress this week, including final tests and training. Following installation of the test bench and prior to commencement of the human trial, a formal phantom study will be completed with formal evaluation by a group of neuroradiologists and vascular neurologists and comprehensive dosimetric information. The RMH is a globally recognised leader in stroke research and care, and home to the Melbourne Brain Centre – the largest brain research collaboration in the southern hemisphere. The trial's academic partner, the Australian Stroke Alliance, brings together more than 40 national organisations committed to improving pre-hospital stroke care in Australia.

Two additional test benches are in advanced construction at Micro-X's manufacturing facility ahead of installation in the second and third trial sites. Parallel to this, Micro-X is advancing the development of the first in-ambulance Head CT prototype, funded through the Australian Government's Industry Growth Program. The first project milestone involving planning and system architecture has been submitted.

Micro-X Chief Operating Officer Anthony Skeats commented:

*"The activation of our first trial site is a major step towards world-first human imaging using carbon nanotube CT developed by Micro-X. Our CT technology has the potential to cut crucial time to stroke diagnosis and the commencement of treatment by bringing miniaturised CT to the patient. As we move through the final stages before the planned commencement of human imaging, we are maintaining our disciplined approach with a focus on data quality and technical excellence. We continue to work closely with the Australian Stroke Alliance as we progress towards this world-first imaging trial using Micro-X's NEX Technology CT."*

Australian Stroke Alliance lead clinical researcher, neurologist Dr Anna Balabanski, commented:

*"This is a significant milestone in the development of this Australian-made portable CT brain scanner. The Royal Melbourne Hospital is an international leader in advanced stroke care. This trial, led by experienced neurologists, radiographers, and radiologists, is a critical step towards enabling safe, high-quality brain imaging in the pre-hospital setting, once these in-hospital trials have demonstrated the device's performance. We are grateful for the support of the Australian Government through the Medical Research Future Fund Frontiers program."*

This ASX Announcement is authorised by the Board of Micro-X.

– ENDS –



## About Micro-X

Micro-X Limited is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control emitter within this technology enables x-ray products providing significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

# MICRO-X

Micro-X's product portfolio spans four high margin product applications in health and security. The first mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. The US Department of Homeland Security has contracted Micro-X to design a next generation airport security checkpoint. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances is being developed with funding from the Australian Government's Medical Research Future Fund. Micro-X is developing a full body CT under contract by US Government agency ARPA-H.

For more information visit: [www.micro-x.com](http://www.micro-x.com)

## Contacts

Micro-X Limited	Investor Enquiries
<b>Kingsley Hall</b> , Chief Executive Officer <b>Rebecca Puddy</b> , Head of Corporate Communications Tel: +61 8 7099 3966 Email: <a href="mailto:media@micro-x.com">media@micro-x.com</a>	<b>David Allen/John Granger</b> Hawkesbury Partners Tel: 0410 577 155 Email: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a> <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>

Clinical Investigation Summary

Study title	The Micro-X Stroke Scanner: A multi-centre prospective pilot study of a novel miniaturised cone beam brain scanner for stroke imaging.
Indication	Patients with (1) ischaemic stroke, (2) intracranial haemorrhage, (3) brain tumor, or (4) stroke mimic
Primary objective	To investigate the ability of the MXS to identify neuroimaging-based contraindications to stroke thrombolysis. To investigate the clinical utility of this scanning technology in reference to its future application for acute stroke assessment.
Study design	Prospective multi-centre non-randomised single group within participant cross-over pilot comparative study.
Sample size	108
Duration of clinical investigation	Estimated as 6 months enrolment period followed by analysis and reporting.